Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model
- 31 August 1996
- journal article
- research article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 23 (6), 851-856
- https://doi.org/10.1016/0969-8051(96)00115-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastomaEuropean Journal Of Cancer, 1995
- Radiation injury to the heartInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell linesJournal of Neuro-Oncology, 1995
- Meta‐[211AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agentInternational Journal of Cancer, 1994
- Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenograftsThe British Journal of Radiology, 1994
- No-carrier-added synthesis of meta-[131I]iodobenzylguanidineApplied Radiation and Isotopes, 1993
- 1-(meta-[211At]Astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluationBioconjugate Chemistry, 1992
- Implications of the uptake of 131I-radiolabelled metaiodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastomaThe British Journal of Radiology, 1991
- Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidineEuropean Journal of Nuclear Medicine and Molecular Imaging, 1988
- Radiochemistry, biochemistry, and kinetics of 131I‐metaiodobenzylguanidine (MIBG) and 123I‐MIBG: Clinical implications of the use of 123I‐MIBGMedical and Pediatric Oncology, 1987